Austrālija - angļu - APVMA (Australian Pesticides and Veterinary Medicines Authority)

kenso corporation (m) sdn. bhd. - diquat present as diquat dibromide; paraquat present as paraquat dichloride - soluble concentrate - diquat present as diquat dibromide pyridine-bipyridyl active 115.0 g/l; paraquat present as paraquat dichloride pyridine-bipyridyl active 135.0 g/l - herbicide - around established trees | avocado | banana | canola oilseed crop | clover pasture | cocksfoot | cotton | custard apple | demete - african turnip weed - seedling | annual broadleaf weed | annual grass weed | annual saltbush - seedling | annual weeds | australian bindweed | australian bindweed - seedling | australian bluebell - seedling | awnless barnyard grass - seedling | barnyard grass or water grass | barnyard or water grass | barnyard or water grass - seedling | bathurst burr - seedling | bellvine - seedling | black pigweed - seedling | blackberry nightshade - seedling | bladder ketmia | bladder ketmia - seedling | blue top - ageratum/heliotropium spp. | boggabri weed - seedling | broadleaf weeds | broadleaf weeds - see label | buffel grass - seedling | calopo | caltrop or yellow vine | caltrop or yellow vine - seedling | capeweed | caustic weed - seedling | cereal - self-sown | climbing buckwheat - seedling | clover | columbus grass - seedling | common heliotrope | cowvine - seedling | cudweed - seedling | deadnettle - seedling | erodium, crowfoot or storksbill | european bindweed - seedling | fat hen - seedling | fireweed - seedlin

Austrālija - angļu - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - diquat present as diquat dibromide; paraquat present as paraquat dichloride - soluble concentrate - diquat present as diquat dibromide pyridine-bipyridyl active 115.0 g/l; paraquat present as paraquat dichloride pyridine-bipyridyl active 135.0 g/l - herbicide - around established trees | avocado | barley - see label | canola - see label | cereal rye - see label | chickpea - see label | c - african turnip weed - seedling | annual grasses - see label | annual ground cherry | annual or wimmera ryegrass - seedling | annual pasture | annual saltbush - seedling | annual weeds | annual weeds - see label | australian bindweed - seedling | australian bluebell - seedling | awnless barnyard grass - seedling | ball mustard - seedling | barley grass - seedling | barnyard grass - seedling | barnyard grass or water grass | barnyard or water grass - seedling | bathurst burr - seedling | bedstraw seedling | bellvine - seedling | bifora - seedling | black pigweed - seedling | blackberry nightshade - seedling | bladder ketmia | bladder ketmia - seedling | bluetop - seedling | boggabri weed | broadleaf weeds | broadleaf weeds - see label | broadleaf weeds and grasses - see label | brome grass - seedling | buffel grass - seedling | calopo - seedling | caltrop or yellow vine - seedling | capeweed | capeweed - seedling | caustic weed - seedling | charlock - seedling | climbing buckwheat - seedling | clover | columbus

Austrālija - angļu - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bayer cropscience pty ltd - triadimenol; n-methylpyrrolidone - emulsifiable concentrate - triadimenol triazole active 250.0 g/l; n-methylpyrrolidone solvent other 602.0 g/l - fungicide - turf - black helminthosporium | dollar spot | fusarium turf patch | take-all patch

Izraēla - angļu - Ministry of Health

novartis israel ltd - dexamethasone; neomycin as sulfate; polymyxin b sulfate - ophthalmic suspension - dexamethasone 1.0 mg/ml; neomycin as sulfate 3,500 iu/ml; polymyxin b sulfate 6000 iu/ml - polymyxin b - polymyxin b - maxitrol is indicated in ocular inflammation when concurrent use of antimicrobial in judged necessary.

Izraēla - angļu - Ministry of Health

novartis israel ltd - dexamethasone; neomycin as sulfate; polymyxin b sulfate - ophtalmic ointment - dexamethasone 1 mg/g; neomycin as sulfate 3500 iu/g; polymyxin b sulfate 6000 iu/g - dexamethasone and antiinfectives - dexamethasone and antiinfectives - for the treatment of eye infections which are responsive to steroids, when an antibiotic is also needed.

Eiropas Savienība - angļu - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - human papillomavirus type 6 l1 protein, human papillomavirus type 11 l1 protein, human papillomavirus type 16 l1 protein, human papillomavirus type 18 l1 protein - papillomavirus infections; uterine cervical dysplasia; condylomata acuminata; immunization - vaccines - gardasil is a vaccine for use from the age of 9 years for the prevention of:premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic human papillomavirus (hpv) types;genital warts (condyloma acuminata) causally related to specific hpv types.see sections 4.4 and 5.1 for important information on the data that support this indication.the use of gardasil should be in accordance with official recommendations.

Austrālija - angļu - APVMA (Australian Pesticides and Veterinary Medicines Authority)

crop culture pty ltd - clopyralid present as the potassium salt - water soluble granules - clopyralid present as the potassium salt pyridine active 750.0 g/kg - herbicide

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine; human immunoglobulin a - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a-routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals, household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, administration of normal immunoglobulin-vf should be considered for all those exposed to the source. institutional contacts. staff in institutions where hepatitis is endemic. routine prophylaxis is not recommended for school, office, factory or hospital contacts. rubella, although normal immunoglobulin-vf can prevent or modify the clinical disease in susceptible rubella contacts if given within 72 hours of exposure, it does not prevent viraemia in such patients. it should, therefore, not be relied upon to prevent congenital malformations due to rubella if given to susceptible pregnant women during the first trimester. measles (morbilli), normal immunoglobulin-vf is indicated for protection against measles in persons exposed less than one week previously. it is recommended in children under six months of age whose mothers have not had the disease, in children between six months and three years of age who have not been actively immunised and in immunosuppressed contacts of the index case. poliomyelitis, normal immunoglobulin-vf is recommended for susceptible contacts who have not been immunised against poliomyelitis.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - normal immunoglobulin, quantity: 320 mg - injection, solution - excipient ingredients: glycine; human immunoglobulin a - normal immunoglobulin-vf is indicated in the management of congenital and acquired forms of primary hypogammaglobulinaemia. it may also be of value in treating secondary forms of this disorder as in leukaemia, nephrosis and acute protein-losing enteropathy, particularly when there is a tendency to recurrent infection. in susceptible contacts of hepatitis a, measles and poliomyelitis, normal immunoglobulin-vf may be of value in preventing or modifying the disease. in general, the earlier in the incubation period of these diseases normal immunoglobulin-vf is given, the greater its effectiveness. hepatitis a-routine passive protection is recommended in persons exposed less than one week previously for the following categories of individuals, household contacts of an index case, who have not already had hepatitis a or have no serological evidence of immunity to the virus. common source exposures. when a vehicle such as food or water is identified as a common source of infection for multiple hepatitis cases, administration of normal immunoglobulin-vf should be considered for all those exposed to the source. institutional contacts. staff in institutions where hepatitis is endemic. routine prophylaxis is not recommended for school, office, factory or hospital contacts. rubella, although normal immunoglobulin-vf can prevent or modify the clinical disease in susceptible rubella contacts if given within 72 hours of exposure, it does not prevent viraemia in such patients. it should, therefore, not be relied upon to prevent congenital malformations due to rubella if given to susceptible pregnant women during the first trimester. measles (morbilli), normal immunoglobulin-vf is indicated for protection against measles in persons exposed less than one week previously. it is recommended in children under six months of age whose mothers have not had the disease, in children between six months and three years of age who have not been actively immunised and in immunosuppressed contacts of the index case. poliomyelitis, normal immunoglobulin-vf is recommended for susceptible contacts who have not been immunised against poliomyelitis.

Izraēla - angļu - Ministry of Health

glaxo smith kline (israel) ltd - neisseria meningitides group b strain nz98/254; neisseria meningitidis group b fhbp fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b nhba fusion protein - suspension for injection - neisseria meningitides group b strain nz98/254 25 mcg; neisseria meningitidis group b fhbp fusion protein 50 mcg; neisseria meningitidis group b nada protein 50 mcg; neisseria meningitidis group b nhba fusion protein 50 mcg - meningococcus b, outer membrane vesicle vaccine - bexsero is indicated for active immunization of individuals from 2 months of age and older against invasive meningococcal disease caused by neisseria meningitidis group b.